东菱精纯克栓酶治疗急性脑梗塞的临床观察

目的：观察东菱精纯克栓酶（ＤＦ５２１）治疗急性脑梗塞的临床疗效。方法：６０例经临床和脑ＣＴ扫描或磁共振成像检查确诊的急性脑梗塞患者，随机分为ＤＦ５２１治疗组（３０例）和复方丹参注射液对照组（３０例）。２组均于治疗前和治疗后第１４日作神经功能缺损评分，结合治疗后患者的病残程度评定疗效。结果：治疗组总有效率（９０．０％）明显高于对照组（６６．７％），Ｐ＜０．０５。２种治疗药物对凝血功能均无明显影响。结论：东菱精纯克栓酶可作为急性脑梗塞早期治疗安全、有效的新药。

Clnical observation on tobishi batroxobin treating acute cerebral infarction

Objective:To observe the clinical therapeutic efficacy of tobishi batroxobin (DF521) on acute cerebral infarction.Methods:Sixty cases of acute cerebral infarction diagnosed by CT scanning or magnetic resonance image(MRI) were divided randomly into 2 groups:treatment group(30 cases) was treated with DF521 and control group (30 cases) was treated with composite salvia miltiorrhiza injection,the neural functional defect of both groups were scored before and the fourteenth day after treatment.Then,combine with the degree of pathological disability after treatment to determine the therapeutic efficacy.Results:The therapeutic effective rate in treatment group was 90 0%,it is higher significantly than control group (66 7%), P <0 05.Moreover,the both drugs did not influence on blood coagulation.Conclusions:DF521 is an effective and safe new method for early treating acute cerebral infarction.